OA

Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight

Retrieved on: 
Monday, June 26, 2023
Weight, Yale School of Medicine, Insulin, Obesity, Diabetes, Doctor of Philosophy, Metabolism, Triglyceride, The New England Journal of Medicine, Yale Center for Environmental Law & Policy, Yale school, OSA, Associate, NEJM, OA, LLY, Lilly, American Diabetes Association, Overweight, Endocrinology, Biology, GIP, Eli Lilly and Company, Obstructive sleep apnea, NYSE, Safety, Conditional sentence, Glycated hemoglobin, Pharmaceutical industry, Medicine, MD

INDIANAPOLIS, June 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today new phase 2 data from retatrutide, Lilly's investigational molecule being studied for the treatment of obesity. At 24 weeks, retatrutide (1 mg, 4 mg, 8 mg or 12 mg) met the primary endpoint for the efficacy estimand in participants living with obesity or overweighti without diabetes, demonstrating a mean weight reduction up to 17.5% (41.2 lb. or 18.7 kg)ii. In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% (57.8 lb. or 26.2 kg)ii at the end of the 48-week treatment duration. The results were presented in a symposium at the American Diabetes Association's® 83rd Scientific Sessions and were simultaneously published in The New England Journal of Medicine (NEJM).

Key Points: 
  • In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% (57.8 lb.
  • The results were presented in a symposium at the American Diabetes Association's® 83rd Scientific Sessions and were simultaneously published in The New England Journal of Medicine (NEJM).
  • Longer duration phase 3 trials will enable comprehensive evaluation of efficacy and tolerability of this potential pharmacotherapeutic for the treatment of obesity."
  • "These phase 2 data have given us confidence to further explore the potential of retatrutide in phase 3 trials that will look beyond weight reduction and focus on treating obesity and its complications comprehensively."

Angry@Arthritis Founder and Osteoarthritis Patient Steve O’Keeffe Applauds ARPA-H Moonshot to Find a Cure as He Works to Eliminate Joint Replacements

Retrieved on: 
Monday, June 26, 2023
Research, Consumer, Healthcare Reform, Public Policy, Other Consumer, Science, Surgery, Seniors, FDA, Health, Government, Physical Therapy, NITRO, Advanced Research Projects Agency for Health, DARPA, Arthritis, Capitol Hill, Arthritis Foundation, Multimedia, ARPA, OA, Joint, News, Pharmaceutical industry, Osteoarthritis

Osteoarthritis (OA) cripples 1 in 7 American adults.

Key Points: 
  • Osteoarthritis (OA) cripples 1 in 7 American adults.
  • That’s more than 32 million people – including tech entrepreneur and non-profit Angry@Arthritis founder Steve O’Keeffe.
  • That’s unacceptable, and yet every year Americans get 2.5 million of these replacements because it’s our only option.
  • We’re thrilled ARPA-H announced an OA moonshot to find out if we can help our joints heal themselves.

Obesity Canada and Lilly advance Canadian obesity research with a new fellowship program

Retrieved on: 
Monday, June 12, 2023
Canada, University of Alberta, Occupational safety and health, Osteoarthritis, Partnership, Obesity, Surgeon, Employment, Miss Universe Canada, University, Communications Research Centre Canada, Body composition, Obesity Canada, Food, CAD, Facial muscles, Research, Doctor of Philosophy, Science, OA, Patient, McGill University, Body mass index, BMI, Elective surgery, Science and technology in Asia, Knee, Disease, Medical device, Nursing, RD, Biostatistics

TORONTO, June 12, 2023 (GLOBE NEWSWIRE) -- Obesity Canada and Lilly Canada are proud to highlight the important work of two researchers who have been selected as recipients of the Canadian Obesity Fellowship Program, in its inaugural year.

Key Points: 
  • TORONTO, June 12, 2023 (GLOBE NEWSWIRE) -- Obesity Canada and Lilly Canada are proud to highlight the important work of two researchers who have been selected as recipients of the Canadian Obesity Fellowship Program, in its inaugural year.
  • Created in 2023, the fellowship program is intended to engage new and emerging academic researchers with an opportunity to conduct obesity-related research that supports the development of a national obesity care framework.
  • Dr. Soren Harnois-Leblanc and Dr. Kristine Godziuk presented their research projects at the 8th Canadian Obesity Summit, in May.
  • The Canadian Obesity Fellowship Program is made available through Obesity Canada in partnership with various stakeholders such as Lilly Canada and is intended for individuals who are currently a postdoctoral fellow affiliated with Canadian Universities who are undertaking obesity research and supervised by a full-time faculty member employed at a Canadian University.

Levolta Pharmaceuticals Partners with Tabuk Pharmaceuticals for Commercialization of Investigational Osteoarthritis Therapy in Middle East and Africa

Retrieved on: 
Thursday, June 1, 2023
Ketan, Osteoarthritis, Business development, Partnership, Physical disability, Central nervous system, Arthritis, Disability, Osteonecrosis of the jaw, MEA, Multimedia, Musculoskeletal disorder, Phase II, OA, MRI, Patient, Council, Rheumatology, Joint, Human musculoskeletal system, Disease, Pharmaceutical industry, Kingdom

BETHLEHEM, Pa., June 1, 2023 /PRNewswire/ -- Levolta Pharmaceuticals , Inc. has entered into an exclusive licensing and distribution agreement for VOLT01 with Tabuk Pharmaceutical Manufacturing Company of Riyadh, Saudi Arabia, for the commercialization of an investigational osteoarthritis (OA) therapy in the Middle East and Africa (MEA) region, excluding South Africa.

Key Points: 
  • BETHLEHEM, Pa., June 1, 2023 /PRNewswire/ -- Levolta Pharmaceuticals , Inc. has entered into an exclusive licensing and distribution agreement for VOLT01 with Tabuk Pharmaceutical Manufacturing Company of Riyadh, Saudi Arabia, for the commercialization of an investigational osteoarthritis (OA) therapy in the Middle East and Africa (MEA) region, excluding South Africa.
  • Tabuk is the market leader in MEA and will be a valuable partner in fulfilling that mission."
  • Tabuk Pharmaceuticals, a fully owned subsidiary of Astra Industrial Group, will hold the marketing authorization and be responsible for registering, importing, and commercializing VOLT01 in the MEA region.
  • "At Tabuk Pharmaceuticals, we believe in our vital role to provide patients across the Middle East and Africa with unique healthcare solutions that support their wellbeing," said Mohammed Al Hagbani, CEO of Tabuk Pharmaceuticals and President of Astra Industrial Group.

Promising New Treatment for Chronic Knee Pain

Retrieved on: 
Tuesday, May 23, 2023
Radiology, General Health, Health, Surgery, Osteoarthritis, Interventional radiology, Society, Arthritis, Disability, Knee, Society of Interventional Radiology, Glomus tumor, Woman, Medicine, Inflammation, De Young, Blood, Knee pain, OA, Patient, Pain management, Ageing, GAE, Chronic pain, Dentistry

La Jolla Vein & Vascular offers novel treatment for chronic knee pain due to osteoarthritis (OA).

Key Points: 
  • La Jolla Vein & Vascular offers novel treatment for chronic knee pain due to osteoarthritis (OA).
  • The treatment, called geniculate artery embolization (GAE), is a minimally-invasive procedure for patients with knee pain who have failed conservative therapy, such as medications, knee injections and are either not eligible or do not wish to undergo knee replacement surgery.
  • Osteoarthritis is the leading cause of chronic pain and disability in the United States.
  • It is estimated that 13% of women and 10% of men aged 60 years and older have symptomatic knee OA.

Favorable Five-Year Survivorship of Implantable Shock Absorber and Reduction of Arthroplasty Risk in High-Risk Patients Reported in Peer-Reviewed Publications

Retrieved on: 
Tuesday, May 23, 2023
Health Technology, Health, Medical Devices, Survival rate, Osteoarthritis, Sports medicine, Mayo Clinic, Orthopedic surgery, Oregon Health & Science University, Arthroplasty, Instrument, Doctor of Philosophy, OA, Rehabilitation, MD, Standard of care, Patient, Risk, School, SUNY Downstate Health Sciences University, ISA, Paper, Clinical professor, Knee, Medical device, Dentistry

For patients suffering with knee OA but not ready for a knee replacement, the potential to delay arthroplasty is a significant attraction.

Key Points: 
  • For patients suffering with knee OA but not ready for a knee replacement, the potential to delay arthroplasty is a significant attraction.
  • Data from three clinical studies show that implantation of the ISA in symptomatic patients with knee OA resulted in a five-year freedom from arthroplasty rate of 85%.
  • This analysis, stratified patients for arthroplasty risk using the SIFK Score, a validated clinical tool developed by researchers at the Mayo Clinic.
  • 2,3 Patients with high-risk SIFK scores are a clearly-defined population at greatly increased risk of near-term arthroplasty when treated with only non-surgical care.

COYNE PR CELEBRATES TRIPLE WIN AT THE 2023 PRWEEK U.S. HEALTHCARE + PHARMA AWARDS

Retrieved on: 
Thursday, May 25, 2023
Osteoarthritis, Social media, TKR, Pain, OA, T-Pain, L'Oréal, Conference

PARSIPPANY, N.J., May 25, 2023 /PRNewswire/ -- Coyne Public Relations, a leading full-service communications firm, with one of the nation's top healthcare practices, proudly announces its three prestigious accolades secured at the PRWeek U.S. Healthcare + Pharma Awards held yesterday evening. Recognized for its innovative and impactful campaigns in the health sector, Coyne PR received more campaign awards than any other agency, including Best in Health Innovation, Best in Social Media and/or Influencers, and Best Pharmaceutical Product Launch.

Key Points: 
  • Coyne PR's approach in health communications, particularly for client Pacira BioSciences, Inc., led to winning the Best in Health Innovation award.
  • And finally, Coyne PR also clinched the Best Pharmaceutical Product Launch award for the successful roll-out of Alka-Seltzer Hangover Relief.
  • This triple win underscores Coyne PR's dedication to maintaining excellence and its stature as an industry leader.
  • For a full list of winners and more information on the PRWeek U.S. Healthcare Conference & Awards, please click here .

Hope for knee osteoarthritis sufferers with advent of global clinical trial.

Retrieved on: 
Wednesday, May 24, 2023
Paradigm, Osteoarthritis, Disease, Obesity, Depression, Hip, Life, Arthritis, Horse, Veterinarian, Anxiety, Biopharma LLC, Quality of life, Gamer, Pain, OA, Injury, Dog, Chemical oxygen demand, English Football League, Joint, Cat, Family, AFL, Knee, Pharmaceutical industry

MELBOURNE, Australia, May 24, 2023 /PRNewswire/ -- With the launch of a new website dedicated to their global clinical trials (https://hope4OA.com), Paradigm Biopharmaceuticals Ltd. (Paradigm Biopharma) aims to provide relief to millions of osteoarthritis (OA) sufferers worldwide by developing a new injectable drug.

Key Points: 
  • Due to their weight bearing role, 70% of all cases affect the hip or the knee.
  • Ex-Australian Football League (AFL) player Greg 'Diesel' Williams understands all too well how knee OA can have a devastating impact on your life.
  • Dr Philip Bloom comments "Osteoarthritis of the knee is not just an isolated pain in the knee.
  • Paradigm Biopharma aims to provide hope to OA sufferers by developing a drug to help relieve pain and improve symptoms in people with knee OA.

Grünenthal's resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee

Retrieved on: 
Monday, May 22, 2023
Osteoarthritis, Nobel Prize, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Transience, Shionogi, Marketing, Perception, Breakthrough therapy, TRPV1, Temperature, II, Pain, OA, Acquisition, Patient, European, Joint, Nobel Prize in Physiology or Medicine, System, FDA, Breakthrough, RTX, Food, Safety, Knee, Pharmaceutical industry, Medicine, Physiology

Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain.

Key Points: 
  • Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain.
  • Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid therapy, in adults with pain associated with knee osteoarthritis.
  • AACHEN, Germany, May 22, 2023 /PRNewswire/ -- Grünenthal today announced that its investigational non-opioid medicine resiniferatoxin (RTX), currently undergoing clinical Phase III development, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for pain associated with osteoarthritis (OA) of the knee.
  • We are hopeful that the Breakthrough Therapy Designation will help us to bring this non-opioid therapy option more quickly to patients."

Grünenthal's resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee

Retrieved on: 
Monday, May 22, 2023
Osteoarthritis, Nobel Prize, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Transience, Shionogi, Marketing, Perception, Breakthrough therapy, TRPV1, Temperature, II, Pain, OA, Acquisition, Patient, European, Joint, Nobel Prize in Physiology or Medicine, System, FDA, Breakthrough, RTX, Food, Safety, Knee, Pharmaceutical industry, Medicine, Physiology

Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain.

Key Points: 
  • Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain.
  • Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid therapy, in adults with pain associated with knee osteoarthritis.
  • AACHEN, Germany, May 22, 2023 /PRNewswire/ -- Grünenthal today announced that its investigational non-opioid medicine resiniferatoxin (RTX), currently undergoing clinical Phase III development, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for pain associated with osteoarthritis (OA) of the knee.
  • We are hopeful that the Breakthrough Therapy Designation will help us to bring this non-opioid therapy option more quickly to patients."